02
Jul

The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $6 million Series A from Morningside.

…read more

Source: Neuropsychiatric biotech raises $20M for PhII program

    

0 No comments